Research programme: orexin receptor modulators - Reset Therapeutics

Drug Profile

Research programme: orexin receptor modulators - Reset Therapeutics

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Reset Therapeutics
  • Developer National Institutes of Health (USA); Reset Therapeutics
  • Class Small molecules
  • Mechanism of Action Hypocretin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Narcolepsy

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Narcolepsy in USA
  • 17 Mar 2016 Orexin receptor modulators licensed to Alkermes plc worldwide
  • 07 Jan 2013 Reset Therapeutics and the National Institutes of Health (USA) form a 5-year collaborative agreement for development of a therapy for narcolepsy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top